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This open-label, prospective study was conducted to compare the impact of epoetin b vs standard care on quality of life (QoL) in
anaemic patients with lymphoid or solid tumour malignancies. A total of 262 anaemic patients (haemoglobin [Hb]p11gdl
 1) were
randomised to a 12-week treatment with s.c. epoetin b (initial dose 150IUkg
 1 three times weekly) or standard care. Transfusions
were recommended for both groups at an Hb threshold of 8.5gdl
 1. The primary efficacy variables were improvement in QoL as
measured using the Short-Form-36 physical component summary (SF-36 PCS) score and the Functional Assessment of Cancer
Therapy fatigue and anaemia subscales (FACT-F and FACT-An). A visual analogue scale (VAS) was also used as a global QoL
measure. Clinical response was defined as a X2gdl
 1 increase in Hb level without need of transfusion after the initial 4 weeks of
treatment. Baseline to final visit changes in SF-36 PCS, FACT-F and VAS scores were significantly greater with epoetin b than with
standard care (Po0.05); changes in FACT-An subscale score tended to be greater with epoetin b (P¼0.076). Epoetin b significantly
increased Hb concentrations relative to standard care (responders: 47% vs 13%; Po0.001). Levels of endogenous erythropoietin
o50mIUml
 1 were significantly predictive of response (OR 2.496, 95% CI: 1.21–5.13). Epoetin b therapy significantly improves
QoL compared with standard care in anaemic patients with solid tumours and lymphoid malignancies.
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Anaemia is a common problem in malignancy. Studies indicate
that approximately 20–50% of cancer patients undergoing
chemotherapy will require blood transfusions for anaemia
(Skillings et al, 1993; Manegold, 1998). This percentage may be
markedly increased with dose intensification and multiple cycles of
chemotherapy (Groopman and Itri, 1999) such that, in those
treated with platinum-based regimens, the frequency of transfu-
sion requirements can reach 100% (Kaye et al, 1992; Nowrousian,
1998). The clinical manifestations of anaemia, such as fatigue,
vertigo, dyspnoea, loss of appetite, inability to concentrate and
cardiovascular problems, impair patients’ functional status and
sense of well-being. Typically, energy levels and exercise tolerance
are considerably reduced, everyday chores become a burden and
social activities are curtailed (Curt et al, 2000). Moreover,
unrelieved anaemia is a negative prognostic factor for outcome
of cancer treatment, such that anaemic cancer patients have a
higher rate of relapse and mortality at the same stage of disease
compared with patients who are not anaemic (Moullet et al, 1998;
Grogan et al, 1999; Caro et al, 2001). Considerable impetus
therefore exists to provide effective management of anaemia in
patients with cancer.
Until recently, blood transfusion therapy represented the sole
treatment option for relief of cancer- or chemotherapy-related
anaemia. However, transfusion is only effective in the short term,
has associated risks (e.g. alloimmunisation and risk of transmis-
sion of infection) and is subject to limitations in blood supply.
Thus, blood transfusions should be reserved for cases of life-
threatening anaemia. In contrast, treatment with recombinant
human erythropoietin (epoetin) leads to a long-lasting increase in
the number of erythroid progenitor cells and red blood cell count,
and is effective and safe for the alleviation of anaemia and
transfusion requirements in patients with cancer (Cazzola et al,
1995; Rose et al, 1995; Dammacco et al, 1998; ten Bokkel Huinink
et al, 1998). Epoetin also improves quality of life (QoL) in anaemic
cancer patients; however, only a few randomised studies have
shown this (Dammacco et al, 2001; Littlewood et al, 2001;
O ¨sterborg et al, 2002), with most data coming from large,
nonrandomised, community-based studies (Glaspy et al, 1997;
Demetri et al, 1998; Gabrilove et al, 2001). Thus, there is a need for
additional well-designed, randomised trials to evaluate the specific
QoL effects of epoetin in the setting of cancer-related anaemia. The
present study was therefore undertaken to assess the impact of
epoetin b on QoL compared with standard care in anaemic
patients with lymphoid or solid tumour malignancies.
MATERIALS AND METHODS
Study design
This was an open-label, randomised, parallel-group, multicentre,
multinational clinical trial, conducted between October 1996 and
September 1998 in patients with chronic anaemia associated with Revised 7 November 2002; accepted 10 December 2002
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lmalignancy. The study was performed in eight countries within
several centres in each country (Austria, n¼5; Belgium, n¼4;
France, n¼7; Germany, n¼1; Italy, n¼5; South Africa, n¼11;
Sweden, n¼2; and the UK, n¼2), and consisted of a run-in period
of up to 14 days followed by a 12-week treatment period. Clinic
visits were scheduled every 3 or 4 weeks during the treatment
period, according to chemotherapy regimen, and every 4 weeks for
patients off chemotherapy.
Patients were randomised (1:1, stratified according to centre) to
receive either epoetin b or standard care (control) with transfusion
support. Epoetin b (NeoRecormon
s, F Hoffmann-La Roche Ltd,
Basel, Switzerland) was administered s.c., by the patients
themselves, relatives or health-care personnel, commencing at a
dose of 150IUkg
 1 three times weekly. The dose of epoetin b was
increased to 300IUkg
 1 for those patients in whom haemoglobin
(Hb) levels increased by o0.5gdl
 1 after 3–4 weeks or o1gdl
 1
after 6–8 weeks. The dose was reduced by 50% if the Hb level
increased by 42gdl
 1 per month, while treatment was inter-
rupted if Hb levels increased to 414gdl
 1 (treatment was
recommenced at half the previous dose once the Hb level had
declined to o12gdl
 1). Oral iron supplementation (200–300mg
elemental ironday
 1) was recommended for those patients in
whom transferrin saturation was o15%. Clinical outcomes were
collected at each postbaseline visit during the 12-week treatment
period. QoL was assessed at baseline, after 3–4 and 6–8 weeks’
treatment and at study end. An Hb level of 8.5gdl
 1 was used as a
guide to initiate transfusion throughout all the centres involved in
the study.
The study was performed in accordance with the latest revisions
to the Declaration of Helsinki and Good Clinical Practice, the study
protocol having been approved by a local independent Ethics
Committee of each centre.
Patients
Adult outpatients with anaemia (Hb p11gdl
 1) associated with
multiple myeloma, non-Hodgkin’s lymphoma or chronic lympho-
cytic leukaemia and any solid tumour treated with myelosuppres-
sive chemotherapy, with at least three cycles remaining, were
eligible for study inclusion. In addition, patients were required to
have a WHO performance status of p2 and a life expectancy of
46 months. Patients with anaemia arising for other reasons (iron
or vitamin B12 deficiency, acute bleeding, haemolytic anaemia),
refractory hypertension, severe renal insufficiency (serum creati-
nine of 42.5mgdl
 1 (4220mmoll
 1)), epilepsy or acute infection
were excluded, as were pregnant or lactating women and women of
childbearing age who were practising unreliable contraception.
Any patient scheduled to undergo bone marrow or peripheral stem
cell transplantation during the study period or 4 weeks prior to the
study was also excluded. Written informed consent was obtained
from all patients prior to the conduct of study-related procedures.
EFFICACY CRITERIA
Primary variables
The primary efficacy parameters were the changes, from baseline
to final visit (week 12), in the Short-Form 36 physical component
summary (SF-36 PCS; Ware et al, 1995) score, and the anaemia and
fatigue subscale scores (FACT-An and FACT-F, respectively)
(Cella, 1997; Yellen et al, 1997) of the Functional Assessment of
Cancer Therapy (FACT) anaemia and fatigue questionnaire. All
QoL assessments were performed immediately prior to clinic visits
so that the patients could not be influenced by references to Hb
levels. The translations used for the SF-36 and FACT–F
questionnaires were fully validated.
The SF-36 health survey is a 36-item self-rated instrument
assessing eight domains of health functioning: physical function-
ing, role functioning related to physical status, bodily pain, general
health, vitality, social functioning, role functioning regarding
emotional status and mental health. The eight dimensions can be
combined into a physical component summary (PCS) and a mental
component summary (MCS) score, both obtained by adding
weighted combinations of the eight subscale scores. Scores are
then converted to standardised T scores that have a mean of 50 and
an s.d. of 10 (Ware et al, 1994). The FACT-An was composed of
seven items covering anaemia-related symptoms common to
cancer patients: walking difficulties, dizziness, headache, shortness
of breath, chest pain, lack of interest in sex and lack of motivation
for normal activities. The FACT-F consisted of 13 items related to
fatigue: fatigue, weakness, listlessness, tiredness (four items),
energy, ability to perform daily activities, limitation of social
activities (three items) and need for sleep during the day.
Secondary variables
Change from baseline to final visit in a visual analogue scale (VAS)
was utilised as a global measure of QoL. The linear VAS comprised
a 13.5cm dual polarity straight line with the anchors ‘worst
imaginable health state’ and ‘best imaginable health state’ at either
end. Patients were asked to assess their global QoL state over the
previous week and mark the line accordingly. The QoL assess-
ments were completed by the patient without assistance from the
physician. The FACT-An global score was also assessed as a
secondary efficacy parameter.
The clinical efficacy criterion was clinical response, defined as
an increase in Hb concentration of X2gdl
 1 during the treatment
phase without transfusion requirement after the initial four
treatment weeks. The haematopoietic response (increase in Hb
of X2gdl
 1 or an increase to X12gdl
 1) was also assessed.
Changes in Hb level between baseline and final visits (independent
variable) and corresponding changes in the primary QoL
parameters (SF-36 PCS, FACT-F, FACT-An and VAS; dependent
variables) were determined. Other variables assessed included
haematocrit (Hct), transfusion requirements, WHO performance
status, iron status, Hb nadirs and endogenous erythropoietin level
including the observed/predicted (O/P) log ratio (Beguin et al,
1992). All blood samples were taken prior to administration of
chemotherapy (if applicable) and study drug, as well as before
blood transfusions.
Safety
Clinical adverse events were recorded throughout the study and
evaluated by the investigator in terms of causal relation to study
medication. Laboratory safety parameters included serum creati-
nine and platelet, leukocyte, neutrophil and lymphocyte counts.
Resting systolic and diastolic blood pressures were recorded at
each visit. The number of hospitalisations in each group was
recorded, including whether or not they were related to anaemia.
Statistics
Sample size calculations were based on the expected change in
SF-36 PCS score (Ware et al, 1995; Yellen and Cella, 1995). Thus, to
detect a between-group difference in SF-36 PCS score of at least
four points, assuming an s.d. of 10 using a two-sided test with a
statistical power of 80% and a¼2.5%, at least 121 patients/group
were required to complete the study and be evaluable for efficacy.
To allow for dropouts, approximately 310 patients were to be
enrolled. However, this target population could not be achieved
despite prolongation of the recruitment period and expansion of
the number of participating centres.
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lA psychometric evaluation was performed to evaluate how well
the QoL scale items satisfied the assumptions underlying the Likert
method for summated rating. The internal consistency reliability
of each scale score was estimated using Cronbach’s a. Cronbach’s
a, which ranges from 0 to 1, where ‘1’ equals perfect reliability, is
based on the average inter-item correlation and the number of
items. Minimum values equal to or greater than 0.70 have been
recommended for group level comparisons (Nunnaly, 1978).
For QoL assessments only patients for whom values were
available at baseline and at least one follow-up visit were included
in the analysis. The data are presented in its raw form and using
the last observation carried forward (LOCF) approach, for patients
with missing values at the final visit. For the percentage of clinical
responders, Kaplan–Meier estimates and corresponding confi-
dence intervals (CIs) for time to treatment response were
determined, and curves were compared using the log-rank test.
The O/P log serum erythropoietin ratio was derived from reference
regression at the particular Hct or Hb level, and was calculated for
responders and nonresponders to epoetin b. The relation between
endogenous erythropoietin level and response to treatment was
explored using the odds ratio (OR) and relative risks (RR) (Cazzola
and Beguin, 1992).
Appropriate parametric and nonparametric tests were used to
analyse between-group differences for continuous and categorical
variables, respectively. All tests were two sided and Po0.05 was
considered significant. Assessment of statistical significance was
not adjusted for multiple comparisons.
RESULTS
Patient demographics
The intention-to-treat population comprised 262 patients aged
24–85 (median 62) years who were enrolled and randomised to
receive either epoetin b (n¼133) or standard care (n¼129). The
baseline demographic/clinical and QoL characteristics of the two
treatment groups are summarised in Tables 1 and 2, respectively.
Overall, there were no significant between-group differences in
baseline demographics and clinical characteristics (Table 1),
except for a significantly higher proportion of patients in the
control group having received prior chemotherapy (80 vs 68%;
P¼0.025).
With respect to QoL measures, baseline scores on the FACT-An
subscale were comparable between treatment groups, although
those randomised to epoetin b therapy had lower FACT-F subscale
score relative to the control group (P¼0.02) (Table 2). Some 51
patients (19%) were withdrawn during the study (epoetin b, n¼30
Table 1 Demographic and baseline characteristics of the intention-to-treat population
Epoetin b (n=133) Control (n=129)
Sex, n (%)
Male 46 (35) 52 (40)
Female 87 (65) 77 (60)
Age (year)
Median (range) 62 (24–85) 62 (24–85)
WHO Performance Status, N (%)
0 36 (27) 41 (32)
1 69 (52) 64 (50)
2 27 (20) 24 (19)
Time from diagnosis of anaemia of malignancy (months)
Median (range) 2.1 (0–99) 2.7 (0–102)
Underlying cancer type, N (%)
Lymphoid tumour 74 (56) 71 (55)
Multiple myeloma 23 (17) 22 (17)
Non-Hodgkin’s lymphoma 33 (25) 28 (22)
Chronic lymphocytic leukaemia 14 (11) 20 (16)
Other 4 (3) 1 (o1)
Solid tumour 59 (44) 58 (45)
Ovarian 26 (20) 19 (15)
Bone, connective tissue, skin and breast 9 (7) 12 (9)
Digestive organs, peritoneum 5 (4) 7 (5)
Respiratory and intrathoracic organs 7 (5) 6 (5)
Other 12 (9) 14 (11)
Patients with chemotherapy before study, N (%) 90 (68) 103 (80)*
Chemotherapy
Alkylating agents 40 (30) 40 (31)
Antimetabolites 25 (19) 25 (19)
Plant alkaloids/other natural products 38 (29) 53 (41)
Cytotoxic antibiotics/related substances 25 (19) 27 (21)
Other antineoplastic agents 42 (32) 42 (33)
Other 3 (2) 2 (2)
Median haemoglobin level, gdl
 1 (range) 9.0 (5–13) 9.2 (5–12)
Median serum erythropoietin level, mIUml
 1 (range) 54 (7–1650) 58 (5–4300)
Median serum iron level, mgdl
 1 (range) 63.7 (6–472) 78.8 (4–510)
Median transferrin saturation, % (range) 20.6 (1–97) 29.0 (2–100)
*P=0.025 vs epoetin b group
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l(23%); control, n¼21 (16%)), 20 of them for adverse events
(epoetin b, n¼15 (11%); control, n¼5 (4%)). Other reasons for
withdrawal, including death, loss to follow-up, withdrawal of
consent and protocol violation, were similarly distributed across
the two treatment groups. The average dose of epoetin b over the
study period was 174IUkg
 1 per administration.
Efficacy
Quality of life The primary efficacy population, which included
patients assessable for the SF–36 PCS, FACT-F and FACT-An
scores, comprised 213 patients (epoetin b, n¼104; control,
n¼109).
Reliabilities assessed for SF-36 subscales varied from 0.83 to 0.90
for the pooled patient population. An exception was the General
Health subscale, which exhibited Cronbach’s a coefficient of 0.75.
The reliability was sufficient for group comparisons of the SF-36
PCS. The FACT-F subscale showed high internal consistency, with
reliabilities over 0.9 for every single language, and 0.93 for the
pooled patient population. These and other psychometric proper-
ties, such as predictive and construct validity, were consistent with
those described for the original instruments (Cella, 1997; Yellen
et al, 1997), as reflected in the reliability of the FACT–An global
score, which reached 0.92 over the total patient population
assessable at baseline. In contrast, the FACT-An 7-item subscale
had a Cronbach’s a of 0.68 on the pooled patient population;
however, this is consistent with the findings of the validation study
(0.59 and 0.70 on initial and retest administration, respectively)
(Cella, 1997).
Quality of life scores for the SF-36 PCS, FACT-F and FACT-An
subscales remained stable over time in the control group but
significantly improved in the epoetin b group. Using LOCF data
(n¼104 epoetin b, n¼109 control), the median changes (baseline
to final visit) for the SF-36 PCS (+3.1 points) and FACT-F (+3.0
points) scores were significantly different from those in the control
group (Po0.05), and a trend towards significance was apparent
with respect to the change in the FACT-An subscale score (+1.0
points) (P¼0.076). When the data without LOCF were used,
median point increases for SF-36 PCS (+3.3 points, n¼77,
P¼0.01) and FACT-F (+4.0 points, n¼90, P¼0.001) were slightly
higher with the FACT-An increase remaining the same (+1.0 point,
n¼89, P¼0.068). VAS scores remained stable over time in the
control group but significantly improved in the epoetin b group; in
the epoetin b group, median changes from baseline to final visit
were significantly different from those in the control group (+10.0
vs +1.0 points, P¼0.004 for data with LOCF (n¼111 and n¼112,
respectively) and +10.0 vs +3.0 points, P¼0.001 for data without
LOCF (n¼89 and n¼98, respectively)). The mean change in QoL
scores from baseline in the epoetin b and control groups for the
without LOCF population are shown in Figure 1. Similar
significant results were reported for the global FACT-An score
(data not shown). In the epoetin group, the rate of data points
available at study end when using the raw data was 74% for the SF-
36 PCS, 87% for FACT-F, 86% for FACT-An and 80% for the VAS
score.
Patients with lymphoproliferative malignancies derived at least
as much QoL benefit from epoetin b therapy as patients with solid
tumours; likewise, patients previously exposed to chemotherapy
showed similar QoL benefit with epoetin b as chemotherapy-naı ¨ve
patients (data not shown). However, patients who responded to
epoetin b therapy (i.e. achieved the target Hb response)
experienced a greater improvement in QoL from baseline to final
visit than patients who were nonresponders (i.e. did not achieve
the target Hb response). Patients who responded to epoetin b
therapy had a mean increase of 3.7 points in their SF-36 score, 7.2
points in their FACT-F score and 1.2 points in their FACT-An
subscale scores; the corresponding improvements in the
nonresponder group were 3.1, 3.4 and 0.5 points, respectively.
Changes in SF-36 PCS and FACT-F scores were mediated through
changes in Hb level (Po0.01) as shown by a path analysis where
epoetin b treatment, QoL increase and Hb increase were used as
dependent variables in turn.
Clinical outcomes A significantly higher proportion of patients in
the epoetin b group (47%) than in the control group (13%)
achieved an increase in Hb of X2gdl
 1 (Po0.001) (Table 3). Of
the 63 patients in the epoetin b group who responded, 44 (70%)
reached the target increase in Hb level during weeks 4–8. Defining
the response as an increase in Hb of X2gdl
 1 or an increase to
12gdl
 1 (haematopoietic response) had only marginal effects on
the number of patients responding to therapy (49 and 15% for
epoetin b and control, respectively, Po0.001). A Kaplan–Meier
estimate of the time to response (X2gdl
 1 only) is presented in
Figure 2.
The median change in Hb over the study period for both groups
can be seen in Figure 3, with the overall increase shown in Figure 4
(Po0.001). Subgroup analyses, based on tumour and
chemotherapy status, also consistently favoured epoetin b over
control therapy (Table 4).
Threshold levels of 50mIUml
 1 for serum endogenous ery-
thropoietin and 0.9 for the O/P ratio were used in the analysis of
baseline serum endogenous erythropoietin levels, as defined
previously by Cazzola et al (1996). Endogenous erythropoietin
levels of o50mIUml
 1 were significantly predictive of response
(OR 2.496, 95% CI 1.21–5.13). The baseline erythropoietin O/P
ratio was only predictive of response for patients with nonsolid
tumours. In this patient subset, 52% of patients with a baseline O/P
ratio of o0.9 achieved a response to therapy (Hb increase
X2gdl
 1) compared with 27% of patients with an O/P ratio X0.9
(RR 1.942; 95% CI: 1.031; 3.665; Po0.001). Results were similar
when an alternative definition of haematopoietic response
(X2gdl
 1 or reaching 12gdl
 1) was applied (RR 1.934; 95% CI:
1.131; 3.307; Po0.001).
The median Hb level before transfusion was 7.64gdl
 1 in the
epoetin b group and 7.80gdl
 1 in the control group. Significantly
fewer patients in the epoetin b group than the control group
required transfusions of whole blood or erythrocyte concentrate
Table 2 Baseline quality-of-life characteristics of the intention-to-treat
population
Epoetin b (n=133) Control (n=129)
Baseline quality-of-life score
SF-36 PCS
Mean (SD) 35 (8.4) 38 (9.5)
Median 35 38
Range 17–60 15–60
FACT-F
Mean (SD) 27 (12) 31 (11)*
Median 28 33
Range 1–49 2–51
FACT-An
Mean (SD) 20 (3.8) 21 (4.4)
Median 21 22
Range 6–27 2–28
VAS
Mean (SD) 56 (17) 62 (17)
Median 53 60
Range 11–96 18–96
SF-36 PCS=Short-Form 36, physical component summary; FACT-F=Functional
Assessment of Cancer Therapy-Fatigue; FACT-An=Functional Assessment of Cancer
Therapy-Anaemia; VAS=Visual analogue scale.
*P=0.02 vs epoetin b group.
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Figure 1 Change in quality of life (QoL) score from baseline at weeks 3–4, 6–8 and 12 during epoetin b therapy or blood transfusion as assessed by the
SF-36 PCS, FACT-F, FACT-An and VAS instruments. Data are presented as mean (s.d.) for the patient population without last observation carried forward.
Table 3 Clinical response rates (increase in haemoglobin concentration of X2gdl
 1 and/or increase to 12gdl
 1
without blood transfusion) and change in haemoglobin values from baseline
Epoetin b (n=133) Control (n=129) P-value
Responders (%)
Increase of X2gdl
 1 63 (47) 17 (13) o0.001
Increase of X2gdl
 1 or increase to X12gdl
 1 65 (49) 19 (15)
Median (range) haemoglobin change from baseline (gdl
 1)
All patients 2.1 ( 3 to 8) 0.9 ( 3t o6 ) o0.001
Patients with solid tumours 2.1 ( 1 to 8) 0.9 ( 3t o4 ) F
Patients with lymphoid tumours 1.9 ( 3 to 8) 0.9 ( 3t o6 ) F
No P-values are provided with respect to subgroups analyses.
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Figure 2 Percentage of patients showing a clinical response to therapy
defined as an increase in haemoglobin X2gdl
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transfusion after the initial 4 weeks of treatment.
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Figure 3 Change in median haemoglobin levels in response to epoetin b
(n¼133) or standard care (n¼129) during the study period.
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the course of the whole study (32 vs 52%; P¼0.001). Overall, the
mean number of units transfusedpatient
 1 was reduced by 43.2%
during the treatment period with epoetin b.
A total of 58 patients required iron supplementation during the
study (epoetin b, n¼30; control, n¼28) with the majority being
administered orally. A minority of patients in each group received
parenteral iron (epoetin b, n¼9; control, n¼2). Patients who had
iron status measured at baseline and at study end showed that
those treated with epoetin b had a serum iron deficit of 4.5mgdl
 1,
while control patients showed a median increase of 16.8mgdl
 1
(Po0.01). No clinically relevant changes in transferrin saturation
were observed for either treatment group between baseline and
study end (data not shown).
Safety A total of 221 patients experienced at least one adverse
event during the present study (epoetin b, n¼115 (86%); control,
n¼106 (82%)), leading to the withdrawal of 29 patients (epoetin b,
n¼19 (14%); control, n¼10 (8%)). No relevant between-group
differences were apparent in terms of the incidence or profile of
specific adverse events, the majority of which were attributed to
the underlying disease and/or concomitant chemotherapy
(Table 5). Few adverse events were therefore deemed to be causally
related to study medication. No patient experienced local injection
site reactions during s.c. administration of epoetin b. A serious
adverse event was defined as an adverse event that was fatal or
acutely life threatening, required/prolonged hospitalisation, re-
sulted in persistent or significant disability or resulted in
malignancy or congenital malformation/anomaly. Serious adverse
events occurred in 42% of patients receiving epoetin b and 33% of
patients on control therapy. The most frequent serious adverse
events with epoetin b and control therapy were malignancy
progression (10 vs 13%) and anaemia (8 vs 13%). No clinically
relevant between-group differences were apparent during the study
with regard to laboratory safety tests and blood pressure. In the
epoetin b compared with the control group there was no
significant difference in the mean number (7s.d.) of hospitalisa-
tions per patient (3.874.5 vs 4.174.9; P¼0.52) or hospital days
(11.7713.7 vs 9.4710.3 days; P¼0.46). There was a trend towards
fewer hospital admissions related to anaemia in the epoetin b
group (0.872.2 vs 1.573.6; P¼0.043).
DISCUSSION
The anaemia of malignancy has a significant negative impact on
patients’ QoL. Treatment with blood transfusions is not without
risk and is subject to availability of blood supplies. These factors
have therefore led to the increased use of epoetin for the treatment
of cancer-related anaemia. The current trial assessed the impact of
epoetin b on QoL in patients with lymphoid or solid tumours, and
showed that epoetin b produced improvements in QoL that were
significantly correlated to the changes observed in Hb concentra-
tions. Furthermore, epoetin b was well tolerated and was
significantly superior to standard care in increasing Hb concen-
trations, irrespective of the type of tumour, or the presence and
nature of chemotherapy. The findings are consistent with those
reported in other clinical studies of epoetin (Case et al, 1993;
Cascinu et al, 1994; Henry and Abels, 1994; Dammacco et al,
1998; Nowrousian, 1998; ten Bokkel Huinink et al, 1998; Ludwig,
1999).
Focusing on the nearly ubiquitous problems of fatigue and
anaemia associated with cancer and its treatment, the FACT-F and
FACT-An subscales provide additional insight about patients’ QoL
(Cella, 1997; Yellen et al, 1997). Epoetin b produced significant
improvements in the SF-36 PCS and FACT-F subscale scores
compared with blood transfusion. This finding agrees with that of
a double-blind study, in which epoetin a produced an improve-
ment in the SF-36 PCS score compared with placebo in anaemic
cancer patients receiving nonplatinum chemotherapy (Littlewood
et al, 2001). This improvement was not statistically significant but
the study was powered to detect changes in the FACT-F
questionnaire, not the SF-36 PCS.
The consistent improvement in all primary end points, and in
the secondary end points, reported in this study provides further
support and internal validity to the finding that epoetin b
significantly improves QoL in anaemic cancer patients. From the
perspective of external validity, the study by O ¨sterborg et al (2002)
also revealed that epoetin b was associated with a statistically
significant (Po0.05) increase in the total FACT-An score after 12
and 16 weeks of treatment.
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Figure 4 Median increase in haemoglobin levels in response to epoetin
b (n¼133) or standard care (n¼129) at the end of the study period.
Table 4 Median increase in haemoglobin level stratified by tumour type
and chemotherapy status
Epoetin b (n=133) Control (n=129)
Hb increase
(gdl
 1) n
Hb increase
(gdl
 1) n
All patients 2.1 112 0.9 112
Solid tumour 2.1 45 0.9 51
Nonsolid tumour 1.9 67 0.9 61
With chemotherapy 2.1 74 1.0 88
Without chemotherapy 2.0 38 0.2 24
Table 5 Most common adverse events
a (reported in X5% of patients in
at least one treatment group)
Adverse event Epoetin b (n=133) Control (n=129)
Malignancy progression 33 (25%) 42 (33%)
Anaemia 18 (14%) 33 (26%)
Leucopenia 20 (15%) 19 (15%)
Thrombocytopenia 8 (6%) 13 (10%)
Bronchitis 7 (5%) 8 (6%)
Fever 5 (4%) 10 (8%)
Nausea 6 (5%) 8 (6%)
Pain 9 (7%) 5 (4%)
Pneumonia 9 (7%) 5 (4%)
Asthenia 6 (5%) 7 (5%)
Diarrhoea 11 (8%) 2 (2%)
Infection 8 (6%) 4 (3%)
Sepsis 3 (2%) 7 (5%)
Vomiting 9 (7%) 1 (o1%)
Depression 8 (6%) 1 (o1%)
Headache 7 (5%) 2 (2%)
aAn adverse event was defined as any undesired, noxious or pathological change in a
patient as indicated by signs, symptoms and/or laboratory changes that occurred in
association with the use of a drug or placebo whether considered drug related or not.
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indicated by VAS scores showed a significant increase with epoetin
b relative to control therapy. This is consistent with previous
community-based studies of over 2000 chemotherapy recipients,
showing a significant improvement in mean VAS ratings of energy,
activity and overall QoL following epoetin therapy (Glaspy, 1997;
Glaspy et al, 1997; Demetri et al, 1998). As in the current trial, QoL
improvements in these studies also correlated significantly with
Hb concentrations.
The rates of missing QoL data points at the end of the study
ranged from 13 to 26%, which is highly favourable compared to
other recent QoL studies in cancer patients (Gabrilove et al, 2001;
Littlewood et al, 2001). Data without LOCF analysis provided
larger differences in QoL scores between the two groups in favour
of epoetin b than were shown following LOCF analysis. Thus, the
QoL data from this study are robust and any conclusions drawn
from the QoL data are independent of the method used to handle
the missing data points.
It is possible that the nonblinded nature of this study may have
influenced the increases in QoL observed, as patients would have
been aware that they were receiving epoetin b. However, increases
in the FACT-F and FACT-An scores during this study for patients
with haematological malignancies are comparable with the
increases observed in a recently published double-blind, placebo-
controlled study examining the effects of epoetin b in the same
patient population (Osterborg et al, 2002). Thus, it appears that the
fact that the study was open-label did not unduly influence the
reporting of QoL results.
A reliable method of predicting potential responders and
nonresponders to epoetin therapy would be extremely valuable
in the clinical setting, as this would enable physicians to target
therapy at those patients who are most likely to benefit. A relation
has been demonstrated between defective endogenous erythro-
poietin production and the likelihood of response to epoetin
(Barosi et al, 1994). Furthermore, the endogenous erythropoietin
O/P ratio is an important measure of endogenous erythropoietin
production. In this study, in patients with lymphoid tumours, 52%
of patients with a serum erythropoietin O/P ratio o0.9 achieved
the expected response to therapy (Hb increase X2gdl
 1),
compared with 27% of patients with a baseline O/P ratio X0.9.
This is consistent with the results of previous studies in patients
with multiple myeloma or non-Hodgkin’s lymphoma (Cazzola et al,
1995; O ¨sterborg et al, 1996). O ¨sterborg et al (1996) showed that the
probability of a response to epoetin was highest in patients with an
O/P ratio of p0.9 and Cazzola et al (1995) suggested that a low-
serum erythropoietin level or O/P ratio should be used to identify
patients very likely to respond to – and therefore good candidates
for – epoetin therapy.
This study shows that it is possible to achieve a significant
improvement in the functional status and QoL of cancer patients
using epoetin b. Studies examining the cost-effectiveness of epoetin
used in the cancer setting have produced mixed conclusions, but
these findings are based on clinical trial results from the early-to-
mid 1990s (Cremieux et al, 1999; Sheffield et al, 1997). Findings
from more recently published clinical studies, including this one,
suggest a need to examine the cost-effectiveness of epoetin b taking
into consideration (1) the value of targeting patients using serologic
markers at baseline and early in treatment, (2) the public concern
about the safety of the blood supply and (3) the prospect that better
anaemia management may improve survival.
In conclusion, the results of the current study indicate that,
when compared with transfusion therapy, epoetin b produces a
clinically significant improvement in QoL in patients with anaemia
associated with malignancy. Epoetin b improved physical func-
tioning and well-being as a result of diminished anaemia-related
symptoms as measured by the FACT-An and FACT-F question-
naires. These improvements in QoL accompany and are mediated
through improvements in Hb concentration, and can be achieved
after a few weeks of epoetin b therapy. In addition, baseline
erythropoietin serum levels and the O/P ratio might identify those
patients with lymphoproliferative malignancies who are more
likely to respond to epoetin b. However, the use of the O/P ratio to
predict which patients will respond to rhEPO therapy requires
further study.
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